ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,555
0,93%
Bitcoin
68 644,12
1,32%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Urovant Sciences Ltd (UROV)

  7. Urovant Sciences Ltd (UROV) Actualités

UROV

Urovant Sciences (UROV)

Urovant Sciences Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:UROV
DateHeureSourceTitreSymboleSociété
13/04/202218h02Business WireUrovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual MeetingNASDAQ:UROVUrovant Sciences Ltd
07/03/202217h56Business WireUrovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902NASDAQ:UROVUrovant Sciences Ltd
20/12/202118h11Business WireUrovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mgNASDAQ:UROVUrovant Sciences Ltd
08/11/202114h00Business WireUrovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder PatientsNASDAQ:UROVUrovant Sciences Ltd
01/04/202112h14Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:UROVUrovant Sciences Ltd
31/03/202118h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
30/03/202118h13Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:UROVUrovant Sciences Ltd
29/03/202121h13Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:UROVUrovant Sciences Ltd
29/03/202121h04Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:UROVUrovant Sciences Ltd
29/03/202114h44Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:UROVUrovant Sciences Ltd
29/03/202114h36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:UROVUrovant Sciences Ltd
19/02/202112h11Edgar (US Regulatory)Amended Statement of Ownership: Private Transaction (sc 13e3/a)NASDAQ:UROVUrovant Sciences Ltd
19/02/202112h05Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (definitive) (defm14a)NASDAQ:UROVUrovant Sciences Ltd
16/02/202121h38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:UROVUrovant Sciences Ltd
12/02/202123h43Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:UROVUrovant Sciences Ltd
12/02/202122h05Business WireUrovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 ResultsNASDAQ:UROVUrovant Sciences Ltd
11/02/202114h00Business WireUrovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data & Safety Mon...NASDAQ:UROVUrovant Sciences Ltd
02/02/202112h08Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:UROVUrovant Sciences Ltd
23/12/202022h05Business WireUrovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overact...NASDAQ:UROVUrovant Sciences Ltd
24/11/202022h05Business WireUrovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) P...NASDAQ:UROVUrovant Sciences Ltd
19/11/202014h00Business WireUrovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension StudyNASDAQ:UROVUrovant Sciences Ltd
16/11/202012h30Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:UROVUrovant Sciences Ltd
13/11/202015h36Dow Jones NewsDisney, DraftKings, Palantir, Li Auto: What to Watch When the Stock Market Opens TodayNASDAQ:UROVUrovant Sciences Ltd
12/11/202023h18Business WireUrovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding SharesNASDAQ:UROVUrovant Sciences Ltd
12/11/202023h00PR Newswire (US)Sumitovant Biopharma and Urovant Sciences Announce Sumitovant's Acquisition of Remaining Stake in UrovantNASDAQ:UROVUrovant Sciences Ltd
10/11/202014h00Business WireUrovant Sciences to Present at the Jefferies Virtual London Healthcare ConferenceNASDAQ:UROVUrovant Sciences Ltd
02/11/202022h05Business WireUrovant Sciences Reports Second Quarter Fiscal Year 2020 ResultsNASDAQ:UROVUrovant Sciences Ltd
27/10/202013h00Business WireUrovant Sciences to Report Second Fiscal Quarter 2020 Financial ResultsNASDAQ:UROVUrovant Sciences Ltd
07/10/202014h00Business WireUrovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion PharmaceuticalsNASDAQ:UROVUrovant Sciences Ltd
08/09/202014h00Business WireUrovant Sciences to Present at the H.C. Wainwright & Co. Annual Global Investment ConferenceNASDAQ:UROVUrovant Sciences Ltd
 Showing the most relevant articles for your search:NASDAQ:UROV

Dernières Valeurs Consultées

NASDAQ
AMZN
Amazon.com
EU
AI
Air Liquide
EU
RNO
Renault
EU
ORA
Orange
NYSE
MCD
McDonalds
EU
SGO
Cie de SaintGobain
USI
USTECH100
US Tech 100
NYSE
KO
Coca Cola
EU
GLE
Societe Generale
EU
BNP
BNP Paribas
NASDAQ
MSFT
Microsoft
EU
LR
Legrand
EU
EN
Bouygues
EU
AF
Air FranceKLM
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés